GBA Group Pharma has been under new management since July 1st. Dr. Sabine Gorynia joins GBA Holding GmbH as Managing Director and thus complements the GBA Group management team in an important position. Dr. Gorynia brings decisive qualifications to her new role. As a biochemist with a PhD, she not only has extensive expertise in the scientific field, but thanks to her more than 15 years of professional experience, GBA Group will also benefit from her management skills, something she has proven many times in various management positions.
Prior to joining GBA Group, Dr. Sabine Gorynia successfully served as Managing Director in the oncology division of leading international pharmaceutical service provider Charles River from 2015. Before that, she worked first as a project manager and later as CEO of Oncotest GmbH. At Bayer Schering Pharma in Berlin, she started her career as a laboratory manager in the Protein Technologies unit.
Her academic career is also impressive. Her master's thesis and doctorate, which she completed at Freie Universität Berlin and ITQB in Portugal, were followed by a postdoctoral period at UCLA, Los Angeles in the Department of Biochemistry. Parallel to her professional work, Dr. Gorynia completed her MBA at the Executive School of Management, Technology and Law at the University of St. Gallen in 2015 and last year completed the further education program Business Law & U.S. Law for Leaders.
Steffen Walter, CEO of GBA Group, is looking forward to the collaboration: "With her impressive scientific background, outstanding management skills and international background, Dr. Gorynia is predestined to take over the Pharma division at GBA Group. I am delighted that we have recruited her to our leadership team and that she will continue to drive growth at GBA Group Pharma."
With approximately 500 employees in Germany and Austria GBA Group Pharma is one of the largest and most experienced service providers for pharmaceuticals and biotechnology in Europe. GBA Group Pharma is active in the entire supply and testing chain from drug development to distribution. Preclinical and clinical services are just as much a part of this as, for example, analytical and QP services or central laboratory services
Prior to joining GBA Group, Dr. Sabine Gorynia successfully served as Managing Director in the oncology division of leading international pharmaceutical service provider Charles River from 2015. Before that, she worked first as a project manager and later as CEO of Oncotest GmbH. At Bayer Schering Pharma in Berlin, she started her career as a laboratory manager in the Protein Technologies unit.
Her academic career is also impressive. Her master's thesis and doctorate, which she completed at Freie Universität Berlin and ITQB in Portugal, were followed by a postdoctoral period at UCLA, Los Angeles in the Department of Biochemistry. Parallel to her professional work, Dr. Gorynia completed her MBA at the Executive School of Management, Technology and Law at the University of St. Gallen in 2015 and last year completed the further education program Business Law & U.S. Law for Leaders.
Steffen Walter, CEO of GBA Group, is looking forward to the collaboration: "With her impressive scientific background, outstanding management skills and international background, Dr. Gorynia is predestined to take over the Pharma division at GBA Group. I am delighted that we have recruited her to our leadership team and that she will continue to drive growth at GBA Group Pharma."
With approximately 500 employees in Germany and Austria GBA Group Pharma is one of the largest and most experienced service providers for pharmaceuticals and biotechnology in Europe. GBA Group Pharma is active in the entire supply and testing chain from drug development to distribution. Preclinical and clinical services are just as much a part of this as, for example, analytical and QP services or central laboratory services
